CD1-HM260-100μg / 询价
CD1-HM260-500μg / 询价
CD1-HM260-500μgx2 / 询价
Human CD160 Protein
Recombinant Human CD160 Protein is expressed from HEK293 with hFc tag at the C-Terminus. It contains Gly25-Leu158.[Accession | O95971-1]
The protein has a predicted MW of 41.3 kDa. Due to glycosylation, the protein migrates to 50-60 kDa based on Tris-Bis PAGE result.
Less than 1EU per μg by the LAL method.
> 95% as determined by Tris-Bis PAGE
> 95% as determined by HPLC
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3-6 months after reconstitution.
2-8°C for 2-7 days after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Human CD160 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
The purity of Human CD160 is greater than 95% as determined by SEC-HPLC.
Immobilized Human HVEM, His Tag at 2μg/ml (100μl/Well) on the plate. Dose response curve for Human CD160, hFc Tag with the EC50 of 0.17μg/ml determined by ELISA.
CD160 (also Natural killer cell receptor BY55) is a 27 ‑ 30 kDa member of the Ig superfamily. In human, it is expressed principally on nonmyeloid hematopoietic cells. CD160 antigenis a receptor on immune cells capable to deliver stimulatory or inhibitory signals that regulate cell activation and differentiation. Exists as a GPI-anchored and as a transmembrane form, each likely initiating distinct signaling pathways via phosphoinositol 3-kinase in activated NK cells and via LCK and CD247/CD3 zeta chain in activated T cells.
CD160; BY55; BY55FLJ46513; NK1; NK28
(1)Chabot S , Jabrane-Ferrat N , Bigot K , et al. A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor[J]. Journal of Experimental Medicine, 2011, 208(5):973-986.
